Analytical Data
-
Gene name
EPM2AIP1
- Application
-
Alternative Names
EPM2AIP 1; EPM2A (laforin) interacting protein 1; EPM2A (laforin) IP1; EPM2A-interacting protein 1; Epm2aip1; EPMIP_HUMAN; FLJ11207; KIAA0766; Laforin interacting protein 1; Laforin-interacting protein; My007
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7L775
-
Expression Region
1-607aa
-
AA Sequence
MWMTPKRSKMEVDEALVFRPEWTQRYLVVEPPEGDGALCLVCRRLIVATRERDVRRHYEAEHEYYERYVADGERAALVERLRQGDLPVASFTPEERAARAGLGLCRLLALKGRGWGEGDFVYQCMEVLLREVLPEHVSVLQGVDLSPDITRQRILSIDRNLRNQLFNRARDFKAYSLALDDQAFVAYENYLLVFIRGVGPELEVQEDLLTIINLTHHFSVGALMSAILESLQTAGLSLQRMVGLTTTHTLRMIGENSGLVSYMREKAVSPNCWNVIHYSGFLHLELLSSYDVDVNQIINTISEWIVLIKTRGVRRPEFQTLLTESESEHGERVNGRCLNNWLRRGKTLKLIFSLRKEMEAFLVSVGATTVHFSDKQWLCDFGFLVDIMEHLRELSEELRVSKVFAAAAFDHICTFEVKLNLFQRHIEEKNLTDFPALREVVDELKQQNKEDEKIFDPDRYQMVICRLQKEFERHFKDLRFIKKDLELFSNPFNFKPEYAPISVRVELTKLQANTNLWNEYRIKDLGQFYAGLSAESYPIIKGVACKVASLFDSNQICEKAFSYLTRNQHTLSQPLTDEHLQALFRVATTEMEPGWDDLVRERNESNP
-
Molecular Weight
96.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EPM2AIP1, or EPM2A interacting protein 1, is a protein that has garnered significant attention in the field of molecular biology due to its role in cellular processes related to glycogen metabolism and neurodegenerative diseases. This protein is known to interact with EPM2A, the gene product of the Lafora's disease gene, which is implicated in a rare genetic disorder characterized by epilepsy and progressive neurological decline. The aggregation of glycogen in the brain is a hallmark of Lafora's disease, and EPM2AIP1 has been identified as a crucial player in modulating the stability of EPM2A and hence influencing glycogen accumulation. Understanding the structure and function of EPM2AIP1 is vital for elucidating the molecular mechanisms underlying Lafora’s disease, as well as other glycogen storage disorders. Recent studies have focused on the recombinant expression of EPM2AIP1, allowing researchers to investigate its interactions in vitro and its functional implications in cellular pathways. The use of recombinant technology to produce EPM2AIP1 enables detailed biochemical assays and structural analyses, which can ultimately lead to insights into therapeutic targets for diseases linked to EPM2A dysfunction. Furthermore, characterizing the protein's interactions with other molecular players involved in glycogen metabolism could reveal novel regulatory mechanisms, enhancing our understanding of energy homeostasis in various tissues. Overall, research on EPM2AIP1 is pivotal not only for understanding Lafora’s disease but also for broader implications in metabolic disorders, making it a significant subject of study in contemporary biomedical research.
